ATE452891T1 - Pyrimidopyrimidone als kinaseinhibitoren - Google Patents

Pyrimidopyrimidone als kinaseinhibitoren

Info

Publication number
ATE452891T1
ATE452891T1 AT03771234T AT03771234T ATE452891T1 AT E452891 T1 ATE452891 T1 AT E452891T1 AT 03771234 T AT03771234 T AT 03771234T AT 03771234 T AT03771234 T AT 03771234T AT E452891 T1 ATE452891 T1 AT E452891T1
Authority
AT
Austria
Prior art keywords
pyrimidopyrimidones
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
AT03771234T
Other languages
English (en)
Inventor
Cleo J Chivikas Connolly
Christopher James Deur
James M Hamby
Denton W Hoyer
Chris Limberakis
Jessica Elisabeth Reed
Mel Conrad Schroeder
Clarke Bentley Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE452891T1 publication Critical patent/ATE452891T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03771234T 2002-07-25 2003-07-21 Pyrimidopyrimidone als kinaseinhibitoren ATE452891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39863802P 2002-07-25 2002-07-25
PCT/IB2003/003359 WO2004011465A1 (en) 2002-07-25 2003-07-21 Kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE452891T1 true ATE452891T1 (de) 2010-01-15

Family

ID=31188438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03771234T ATE452891T1 (de) 2002-07-25 2003-07-21 Pyrimidopyrimidone als kinaseinhibitoren

Country Status (18)

Country Link
US (1) US7196090B2 (de)
EP (1) EP1549651B1 (de)
JP (1) JP2005538992A (de)
AR (1) AR040513A1 (de)
AT (1) ATE452891T1 (de)
AU (1) AU2003249442A1 (de)
BR (1) BR0312867A (de)
CA (1) CA2493633C (de)
DE (1) DE60330694D1 (de)
ES (1) ES2335659T3 (de)
GT (1) GT200300150A (de)
HN (1) HN2003000227A (de)
MX (1) MXPA05000814A (de)
PA (1) PA8577501A1 (de)
PE (1) PE20040688A1 (de)
TW (1) TW200413375A (de)
UY (1) UY27906A1 (de)
WO (1) WO2004011465A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
JP4214729B2 (ja) * 2002-07-25 2009-01-28 コニカミノルタホールディングス株式会社 硬化性白インク組成物
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
JP2006522756A (ja) * 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
JP2008510690A (ja) 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用
BRPI0514750A (pt) 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP2327429B1 (de) * 2005-03-23 2014-09-17 Abbott Laboratories Verabreichung stark lipophiler wirkstoffe mittels medizinischer vorrichtungen
US20090221600A1 (en) * 2005-09-28 2009-09-03 Ashwani Kumar Verma Pyrido-pyridimidine derivatives useful as antiinflammatory agents
SI1954697T1 (sl) * 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
EP1951332A1 (de) * 2005-11-10 2008-08-06 Schering Aktiengesellschaft Reduzierung von restenose
DE602006015700D1 (de) * 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
ATE465163T1 (de) 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
AU2007211684A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CN101522676A (zh) 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
EP2114941B1 (de) * 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclische heterocyclische verbindungen als fgfr-inhibitoren
JP2010523653A (ja) 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
WO2008147687A1 (en) * 2007-05-21 2008-12-04 Mayo Foundation For Medical Education And Research Treating pancreatitis
CA2689429C (en) * 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
WO2009016486A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd Use of nmda receptor antagonists for treatment of urologic tumors
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
ATE551342T1 (de) * 2008-02-22 2012-04-15 Irm Llc Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
EP2276748A1 (de) * 2008-04-10 2011-01-26 Gilead Sciences, Inc. Bicyclischen stickstoff enthaltende heterocyclische verbindungen zur verwendung als inhibitoren von stearoyl-coa-desaturase
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6576325B2 (ja) * 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
CA2907243C (en) * 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2016055907A1 (en) 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN104478742A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种氟代化合物及其制备方法
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
BR112019002610A2 (pt) * 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
PE20212303A1 (es) * 2018-12-27 2021-12-10 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
CN116253735B (zh) * 2021-12-10 2025-05-02 江苏开元药业有限公司 嘧啶并嘧啶酮类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
US3912723A (en) * 1971-03-29 1975-10-14 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
EP0786997A4 (de) 1994-10-27 1998-03-11 Merck & Co Inc Muscarinantagonisten
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
AU742999B2 (en) * 1997-08-20 2002-01-17 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
CN1150195C (zh) 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
KR20020027649A (ko) * 1999-09-15 2002-04-13 로즈 암스트롱, 크리스틴 에이. 트러트웨인 카이나제 억제제로서의 프테리딘온
PL357494A1 (en) 1999-10-21 2004-07-26 F.Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
KR100523120B1 (ko) 1999-10-21 2005-10-20 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2001278908A1 (en) * 2000-08-04 2002-02-18 Warner Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones
MXPA03000865A (es) * 2000-08-04 2003-06-18 Warner Lambert Co Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d)pirimidin-7-onas.
JP2004519422A (ja) * 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン

Also Published As

Publication number Publication date
PE20040688A1 (es) 2004-10-06
DE60330694D1 (de) 2010-02-04
WO2004011465A1 (en) 2004-02-05
US7196090B2 (en) 2007-03-27
ES2335659T3 (es) 2010-03-31
AU2003249442A1 (en) 2004-02-16
EP1549651B1 (de) 2009-12-23
TW200413375A (en) 2004-08-01
JP2005538992A (ja) 2005-12-22
CA2493633C (en) 2009-04-07
UY27906A1 (es) 2004-02-27
CA2493633A1 (en) 2004-02-05
AR040513A1 (es) 2005-04-06
EP1549651A1 (de) 2005-07-06
HN2003000227A (es) 2005-10-20
PA8577501A1 (es) 2004-02-07
BR0312867A (pt) 2005-06-14
GT200300150A (es) 2004-06-08
MXPA05000814A (es) 2005-04-19
US20040019210A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
IS7599A (is) Heterósýklískir kínasatálmar
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE368651T1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties